[4] |
NIE J, YANG Y, GAO Y N,et al. Newly self-administered two-step tool for screening cognitive function in an ageing Chinese population:an exploratory cross-sectional study[J]. Gen Psychiatr, 2023, 36(1):e100837. DOI: 10.1136/gpsych-2022-100837.
|
[5] |
QIU J Y, ZHAO L, XIAO S F,et al. Efficacy of comprehensive cognitive health management for Shanghai community older adults with mild cognitive impairment[J]. Gen Psychiatr, 2022, 35(4):e100532. DOI: 10.1136/gpsych-2021-100532.
|
[6] |
中国高血压防治指南(2018年修订版)[J]. 临床医学研究与实践,2019,4(5):201.
|
[7] |
WANG Q, ZHOU S, ZHANG J Y,et al. Risk assessment and stratification of mild cognitive impairment among the Chinese elderly:attention to modifiable risk factors[J]. J Epidemiol Community Health, 2023, 77(8):521-526. DOI: 10.1136/jech-2022-219952.
|
[8] |
PU L N, PAN D G, WANG H H,et al. A predictive model for the risk of cognitive impairment in community middle-aged and older adults[J]. Asian J Psychiatr, 2023, 79:103380. DOI: 10.1016/j.ajp.2022.103380.
|
[9] |
HUANG M L, GAO X X, ZHAO R,et al. Development and validation of a nomogram for predicting mild cognitive impairment in middle-aged and elderly people[J]. Asian J Psychiatr, 2022, 75:103224. DOI: 10.1016/j.ajp.2022.103224.
|
[10] |
LÖVDÉN M, FRATIGLIONI L, GLYMOUR M M,et al. Education and cognitive functioning across the life span[J]. Psychol Sci Public Interest, 2020, 21(1):6-41. DOI: 10.1177/1529100620920576.
|
[11] |
ASSAF G, EL KHOURY J, JAWHAR S,et al. Mild cognitive impairment and modifiable risk factors among Lebanese older adults in primary care[J]. Asian J Psychiatr, 2021, 65:102828. DOI: 10.1016/j.ajp.2021.102828.
|
[12] |
NAJAR J, ÖSTLING S, GUDMUNDSSON P,et al. Cognitive and physical activity and dementia:a 44-year longitudinal population study of women[J]. Neurology, 2019, 92(12):e1322-1330. DOI: 10.1212/WNL.0000000000007021.
|
[13] |
YANG Q, LI S Y, YANG Y,et al. Prolonged sleep duration as a predictor of cognitive decline:a meta-analysis encompassing 49 cohort studies[J]. Neurosci Biobehav Rev, 2024, 164:105817. DOI: 10.1016/j.neubiorev.2024.105817.
|
[14] |
MA Y J, LIANG L R, ZHENG F F,et al. Association between sleep duration and cognitive decline[J]. JAMA Netw Open, 2020, 3(9):e2013573. DOI: 10.1001/jamanetworkopen.2020.13573.
|
[15] |
WINER J R, DETERS K D, KENNEDY G,et al. Association of short and long sleep duration with amyloid-β burden and cognition in aging[J]. JAMA Neurol, 2021, 78(10):1187-1196. DOI: 10.1001/jamaneurol.2021.2876.
|
[16] |
PAK V M, PAUL S, SWIEBODA D,et al. Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease[J]. Alzheimers Dement(N Y), 2022, 8(1):e12332. DOI: 10.1002/trc2.12332.
|
[17] |
BLOOMBERG M, MUNIZ-TERRERA G, BROCKLEBANK L,et al. Healthy lifestyle and cognitive decline in middle-aged and older adults residing in 14 European countries[J]. Nat Commun, 2024, 15(1):5003. DOI: 10.1038/s41467-024-49262-5.
|
[18] |
CHOI D, CHOI S, PARK S M. Effect of smoking cessation on the risk of dementia:a longitudinal study[J]. Ann Clin Transl Neurol, 2018, 5(10):1192-1199. DOI: 10.1002/acn3.633.
|
[19] |
MUÑOZ MANIEGA S, CHAPPELL F M, VALDÉS HERNÁNDEZ M C,et al. Integrity of normal-appearing white matter:influence of age,visible lesion burden and hypertension in patients with small-vessel disease[J]. J Cereb Blood Flow Metab, 2017, 37(2):644-656. DOI: 10.1177/0271678x16635657.
|
[20] |
KÖBE T, GONNEAUD J, BINETTE A P,et al. Association of vascular risk factors with β-amyloid peptide and tau burdens in cognitively unimpaired individuals and its interaction with vascular medication use[J]. JAMA Netw Open, 2020, 3(2):e1920780. DOI: 10.1001/jamanetworkopen.2019.20780.
|
[21] |
LOERA-VALENCIA R, EROLI F, GARCIA-PTACEK S,et al. Brain renin-angiotensin system as novel and potential therapeutic target for Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(18):10139. DOI: 10.3390/ijms221810139.
|
[1] |
JIA L F, DU Y F, CHU L,et al. Prevalence,risk factors,and management of dementia and mild cognitive impairment in adults aged 60 years or older in China:a cross-sectional study[J]. Lancet Public Health, 2020, 5(12):e661-671. DOI: 10.1016/S2468-2667(20)30185-7.
|
[2] |
LIVINGSTON G, HUNTLEY J, LIU K Y,et al. Dementia prevention,intervention,and care:2024 report of the lancet standing commission[J]. Lancet, 2024, 404(10452):572-628. DOI: 10.1016/S0140-6736(24)01296-0.
|
[3] |
SIQUEIRA G S A, HAGEMANN P M S, COELHO D S,et al. Can MoCA and MMSE be interchangeable cognitive screening tools a systematic review[J]. Gerontologist, 2019, 59(6):e743-763. DOI: 10.1093/geront/gny126.
|
[22] |
LEVINE D A, GALECKI A T, LANGA K M,et al. Blood pressure and cognitive decline over 8 years in middle-aged and older black and white Americans[J]. Hypertension, 2019, 73(2):310-318. DOI: 10.1161/HYPERTENSIONAHA.118.12062.
|
[23] |
|
[24] |
FILLER J, GEORGAKIS M K, DICHGANS M. Risk factors for cognitive impairment and dementia after stroke:a systematic review and meta-analysis[J]. Lancet Healthy Longev, 2024, 5(1):e31-44. DOI: 10.1016/S2666-7568(23)00217-9.
|
[25] |
SMITH A D, REFSUM H, BOTTIGLIERI T,et al. Homocysteine and dementia:an international consensus statement[J]. J Alzheimers Dis, 2018, 62(2):561-570. DOI: 10.3233/JAD-171042.
|
[26] |
WEEKMAN E M, WOOLUMS A E, SUDDUTH T L,et al. Hyperhomocysteinemia-induced gene expression changes in the cell types of the brain[J]. ASN Neuro, 2017, 9(6):1759091417742296. DOI: 10.1177/1759091417742296.
|
[27] |
HOSOKI S, HANSRA G K, JAYASENA T,et al. Molecular biomarkers for vascular cognitive impairment and dementia[J]. Nat Rev Neurol, 2023, 19(12):737-753. DOI: 10.1038/s41582-023-00884-1.
|
[28] |
FORTEA J, PEGUEROLES J, ALCOLEA D,et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease[J]. Nat Med, 2024, 30(5):1284-1291. DOI: 10.1038/s41591-024-02931-w.
|
[29] |
LI Z H, MARTENS Y A, REN Y X,et al. APOE genotype determines cell-type-specific pathological landscape of Alzheimer's disease[J]. Neuron, 2025, 113(9):1380-1397.e7. DOI: 10.1016/j.neuron.2025.02.017.
|